Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05598112

Effect of Gut Microbiome Intervention on Aging Via Oral FMT

Effect of Fecal Microbiota Transplantation on Aging and the Underlying Mechanism of Gut Microbiome Restoration: a Randomized Clinical Trial

Status
Recruiting
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
210 (estimated)
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital · Academic / Other
Sex
All
Age
70 Years – 85 Years
Healthy volunteers
Accepted

Summary

A severe public health issue facing global population is aging. Increasing preclinical and clinical data indicate the contribution of gut microbiome on aging and aging-related diseases such as cardiovascular disease, Alzheimer Disease, and diabetes. Interventions on microbiota are developed including prebiotics, probiotics, and fecal microbial transplantation (FMT). FMT via oral capsules also advances in recent with limited safety concerns compared with invasive routes. A hypothesis is thus raised that gut microbiome intervention via oral FMT can be a potential safe approach to encourage healthy aging, with multiple aspects evaluated for clinical phenotype of frailty, anthropometric measurement, cognitive function, cardiovascular aging, physical function, living activity, hippocampal volume, telomere length, cognitive biomarkers, inflammatory biomarkers, altered microbial composition and metabolites.

Detailed description

Objective: To explore the effect, safety and underlying mechanisms of gut microbiome intervention via FMT on aging. Study Design: A multi-center, randomized, blinded, placebo-controlled pilot study. Data quality control and statistical analysis: The investigators have invited professional statistic analysts to assist analyzing data and a third party to supervise data quality. Ethics: The Ethics Committee of Fuwai Hospital approved this study. Informed consents before patient enrollment are required.

Conditions

Interventions

TypeNameDescription
BIOLOGICALFMT capsulesFMT capsules containing extensively screened donor stool.
OTHERPlacebo capsulesPlacebo capsules that do not contain donor stool or any active drug.

Timeline

Start date
2023-04-24
Primary completion
2026-12-31
Completion
2027-12-31
First posted
2022-10-28
Last updated
2025-12-31

Locations

6 sites across 1 country: China

Source: ClinicalTrials.gov record NCT05598112. Inclusion in this directory is not an endorsement.